Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
88.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioNTech SE - American Depositary Shares
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
72
73
Next >
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
September 01, 2022
From
Pfizer Inc.
Via
Business Wire
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
↗
September 01, 2022
Wall Street Journal
Via
Benzinga
Why Novavax Shares Are Getting Hammered After Moderna, Pfizer And BioNTech News
↗
August 31, 2022
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 6.76% to $32.84 Wednesday afternoon in possible reaction to competitor Moderna Inc (NASDAQ: MRNA) receiving FDA authorization for emergency use...
Via
Benzinga
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
August 31, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer, Moderna Nab FDA Authorization For Updated Covid Boosters
↗
August 31, 2022
Boosters are recommended two months out from the last shot.
Via
Investor's Business Daily
Benzinga Before The Bell: Tesla Sues Louisiana Automobile Dealers Association, Will iPhone 14 Feature Satellite Connectivity?, Netflix Denies $7 To $9 Ad-Supported Plan And Other Top Financial Stories Tuesday, August 30
↗
August 30, 2022
Reuters Taiwan’s China Airlines Orders 16 Boeing 787s
Via
Benzinga
US Stock Futures Higher Ahead Of Economic Data, Fed Speakers
↗
August 30, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade as investors digested comments from Federal Reserve Chairman Jerome Powell. Markets closed lower again on Monday, with the...
Via
Benzinga
Pfizer-BioNTech, Moderna Set To Get FDA Nod For Omicron Booster Shots As Early As Wednesday: Report
↗
August 30, 2022
Booster shots for Omicron variants of the novel coronavirus could officially be made available in the U.S. just after Labor Day, Politico reported on Monday.
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
↗
August 26, 2022
Via
Benzinga
Pfizer/BioNTech Complete European Submission For Omicron Subvariant Adapted Vaccine
↗
August 26, 2022
Via
Benzinga
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
August 26, 2022
From
Pfizer Inc.
Via
Business Wire
Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot
↗
August 26, 2022
The lawsuit alleges Comirnaty violates Moderna's patents from 2010-16.
Via
Investor's Business Daily
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
↗
August 26, 2022
Moderna Inc (NASDAQ: MRNA) has
Via
Benzinga
Pfizer And Moderna Are In A Race With Omicron; Will The Vaccine Stocks Be Too Late?
↗
August 26, 2022
The companies hope to launch updated boosters this fall. This is what experts think of their prospects.
Via
Investor's Business Daily
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
↗
August 24, 2022
In a Reuters report, AstraZeneca Plc's (NASDAQ:
Via
Benzinga
Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot
↗
August 23, 2022
Moderna put the finishing touches on its FDA filing Tuesday, trailing its rivals by a day.
Via
Investor's Business Daily
Pfizer/BioNTech's COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers
↗
August 23, 2022
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have
Via
Benzinga
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
August 23, 2022
From
Pfizer Inc.
Via
Business Wire
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
↗
August 22, 2022
Via
Benzinga
Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here's Who May Be Rolling Them Out
↗
August 22, 2022
Via
Benzinga
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
↗
August 22, 2022
Via
Benzinga
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
August 22, 2022
From
Pfizer Inc.
Via
Business Wire
Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday, August 22
↗
August 22, 2022
Reuters Vodafone To Sell Hungarian Business For $1.8B: Report
Via
Benzinga
Canada OKs Pfizer COVID-19 Booster For Kids Aged 5-11 Years
↗
August 22, 2022
Via
Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
↗
August 19, 2022
How they handle an upcoming shift in payments will be telling for their tailwind.
Via
Investor's Business Daily
Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
↗
August 17, 2022
Via
Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
↗
August 17, 2022
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.
Via
InvestorPlace
A Look Into Healthcare Sector Value Stocks
↗
August 15, 2022
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
↗
August 15, 2022
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year...
Via
Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
↗
August 12, 2022
The major indexes continued to advance, despite some key warnings.
Via
Investor's Business Daily
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
72
73
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.